Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13959065 | 0.79 | KDM4C (0.41) | KDM4CMEN1KMT2AEPHX1MMP1 | |
| SCHEMBL1273741 | 0.77 | MMP1 (0.40) | KDM4CKMT2AEPHX1MMP1MMP2 | |
| SCHEMBL13943361 | 0.72 | MMP1 (0.37) | KDM4CKMT2AEPHX1MMP1MMP2 | |
| SCHEMBL4100814 | 0.70 | — | — | |
| SCHEMBL564253 | 0.70 | — | — | |
| SCHEMBL13973081 | 0.70 | — | — | |
| SCHEMBL14997799 | 0.70 | KDM4C (0.37) | KDM4C | |
| SCHEMBL15228190 | 0.69 | — | — | |
| SCHEMBL10446327 | 0.69 | — | — | |
| SCHEMBL16309335 | 0.69 | EPHX1 (0.48) | MEN1KMT2AEPHX1MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | claimed |
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | claimed |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250326761-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4605394-A1 | PYRIMIDINE SGC STIMULATORS | Tisento Therapeutics Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4605080-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH SGC STIMULATORS | Tisento Therapeutics Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250243228-A1 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250243205-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250129060-A1 | SOLID FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2012003405-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011115804-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100144864-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2152266-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | Ironwood Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008137318-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144864-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | GUCY1A2, GUCY1B2, GUCY1B1 | KDM4C 4177/4885MEN1 3134/4885KMT2A 3747/4885 |
| US-20250326761-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | KDM4C 4348/4885MEN1 4282/4885KMT2A 4533/4885 |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | KDM4C 2521/4885MEN1 3036/4885KMT2A 3307/4885 |
| US-20250243228-A1 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORS | P2RY1, P2RY11, GMPS | KDM4C 3389/4885MEN1 2462/4885KMT2A 3926/4885 |
| US-20250129060-A1 | SOLID FORMS OF AN SGC STIMULATOR | GUCY1A2, PRKG1, GUCY1A1 | KDM4C 4103/4885MEN1 2814/4885KMT2A 4402/4885 |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | PDE2A, PRKG1, GUCY1A2 | KDM4C 3169/4885MEN1 3027/4885KMT2A 4127/4885 |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | KDM4C 2521/4885MEN1 3036/4885KMT2A 3307/4885 |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | PDE9A, PDE2A, GUCY1A2 | KDM4C 4155/4885MEN1 1173/4885KMT2A 4514/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KDM4C 3857/4885MEN1 3461/4885KMT2A 4149/4885 |
| US-20250243205-A1 | sGC STIMULATORS | GMPS, GUCY1A2, PDE2A | KDM4C 4101/4885MEN1 3842/4885KMT2A 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.